Neoplastic meningitis from breast cancer: Feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5191-5195

  Hoffmann, A L ^a   Buhk, J H ^a   Strik, Herwig ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Breast cancer; Chemotherapy; DepoCyte ; Leptomeningeal disease; Liposomal Ara C; Neoplastic meningitis; Temozolomide

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GOSERELIN; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBELLUM TUMOR; CEREBROSPINAL FLUID CYTOLOGY; CERVICAL SPINE; DIARRHEA; DISSEMINATED CANCER; DRUG ACTIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; NEOPLASTIC MENINGITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPINAL CORD METASTASIS; SPINE METASTASIS; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYTARABINE; DACARBAZINE; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, SPINAL; LIPOSOMES; MENINGEAL NEOPLASMS;

EID: 75149126753     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R and Winer E: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972-2977, 2003.
2. Balm M and Hammack J: Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 53: 626-632, 1996.
3. DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38: 245-252, 1998.
4. Ongerboer de Visser, Somers R, Nooyen WH, van Heerde P, Hart AA and McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33: 1565-1572, 1983.
5. Grossman SA and Krabak MJ: Leptomeningeal carcinomatosis. Cancer Treat Rev 25: 103-119, 1999.
6. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, Hart AA, Benraadt J and Vecht C: The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40: 2726-2733, 2004.
7. Rudnicka H, Niwinska A and Murawska M: Breast cancer leptomeningeal metastasis - the role of multimodality treatment. J Neurooncol 84: 57-62, 2007.
8. Jayson GC and Howell A: Carcinomatous meningitis in solid tumours. Ann Oncol 7: 773-786, 1996.
9. Chamberlain MC: Neoplastic meningitis. J Clin Oncol 23: 3605-3613, 2005.
10. Chamberlain MC, Kormanik P, Howell SB and Kim S: Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52: 912-917, 1995.
11. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E and Kim S: Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 50: 261-264, 1993.
12. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L and Howell SB: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84: 157-163, 2001.
13. Pentheroudakis G and Pavlidis N: Management of leptomeningeal malignancy. Expert Opin Pharmacother 6: 1115-1125, 2005.
14. Kern DH, Morgan CR and Hildebrand-Zanki SU: In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 48: 117-121, 1988.
15. Bleyer WA: Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clin Cancer Res 5: 3349-3351, 1999.
16. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY and Malkin MG: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53: 259-265, 2001.
17. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P and Throuvalas N: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20: 3644-3650, 2002.
18. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C and Skarlos DV: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: 249-254, 2001.
19. Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S and Eisenhauer E: Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 17: 952-956, 2006.
20. Strik HM, Buhk JH, Wrede A, Hoffmann A, Bock H, Chistmann M and Kaina B: Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Molec Med Rep 1: 863-869, 2008.
21. Bokstein F, Lossos A and Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82: 1756-1763, 1998.
22. Boogerd W, Hart AA, van der Sande JJ and Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67: 1685-1695, 1991.
23. Wasserstrom WR, Glass JP and Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49: 759-772, 1982.
24. van Oostenbrugge RJ and Twijnstra A: Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 53: 382-385, 1999.
25. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P and Egorin MJ: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16: 1561-1567, 1998.
26. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG and Raizer JJ: Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78: 255-260, 2006.
27. Gaviani P, Silvani A, Corsini E, Erbetta A and Salmaggi A: Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. Neurol Sci 30: 251-254, 2009.
28. Pavlidis N: The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol 15(Suppl 4): iv285-iv291, 2004.
29. Chamberlain MC and Kormanik PR: Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 35: 55-64, 1997.
30. Bruna J, Gonzalez L, Miro J, Velasco R, Gil M and Tortosa A: Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115: 381-389, 2009.
31. 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46: 1674-1677, 1996.
32. Chamberlain MC and Kormanik P: Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55: 506-512, 1998.
33. Sause WT, Crowley J, Eyre HJ, Rivkin SE, Pugh RP, Quagliana JM, Taylor SA and Molnar B: Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases - a Southwest Oncology Group study. J Neurooncol 6: 107-112, 1988.
34. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF and Howell SB: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5: 3394-3402, 1999.
35. Glantz M, Chamberlain M, Batchelor T, Eric W, Cavalli F and Shapiro W: Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis. J Clin Oncol Conf Proceedings 24: 1530, 2006.
36. Verger E, Gil M, Yaya R, Vinolas N, Villa S, Pujol T, Quinto L and Graus F: Temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61: 185-191, 2005.
37. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: 1004-1011, 2003.
38. Glas M, Stuplich M, Tschampa H, Urbach H, Rasch K and Herrlinger U: Liposomal cytarabine given concomitantly with radiotherapy in a patient with leptomeningeal metastasis from breast cancer. J Neurol 255: 1838-1839, 2008.
39. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T and Pouillart P: Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors and results of a high-dose intrathecal methotrexate regimen. Cancer 77: 1315-1323, 1996.